Potent neutralizing antibodies (nAbs) against SARS-CoV-2 are a promising therapeutic
against the ongoing COVID-19 pandemic. However, the continuous emergence of …

Emerging severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) variants,
especially the Omicron variant, have impaired the efficacy of existing vaccines and most …

The emergence of SARS-CoV-2 variants that threaten the efficacy of existing vaccines and
therapeutic antibodies underscores the urgent need for new antibody-based tools that …

The highly mutated and transmissible Omicron (BA. 1) and its more contagious lineage BA.
2 have provoked serious concerns over their decreased sensitivity to the current COVID-19 …

Immune evasion of SARS-CoV-2 undermines current strategies tocounteract the pandemic,
with the efficacy of therapeutic virus-neutralizing monoclonal antibodies (nAbs) being …

The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants
of concern threatens the efficacy of existing vaccines and therapeutic antibodies and …

Bispecific antibodies have emerged as a promising strategy for curtailing severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2) immune escape. This brief report …

SARS-CoV-2 Omicron variant has presented significant challenges to current antibodies
and vaccines. Herein, we systematically compared the efficacy of 50 human monoclonal …

Neutralizing antibodies (nAbs) to SARS-CoV-2 hold powerful potentials for clinical
interventions against COVID-19 disease. However, their common genetic and biologic …

New threats posed by the emerging circulating variants of SARS-CoV-2 highlight the need to
find conserved neutralizing epitopes for therapeutic antibodies and efficient vaccine design …